The rediscovery of DON (6-diazo-5-oxo-L-norleucine).

D. L. Kisner*, R. Catane, F. M. Muggia

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


DON (6-diazo-5-oxo-L-norleucine) and azotomycin are glutamine antagonists that were tested in human malignancies in the 1950s. Azotomycin demonstrated significant activity in colorectal cancer. DON is probably the active form of azotomycin. Recent impressive results for both of these agents in human tumor xenografts (especially the CX-2 colon tumor) have stimulated renewed clinical interest in DON, the more readily available agent. DON mechanism of action, clinical pharmacology, previous clinical data, and current phase I studies are discussed.

Original languageEnglish
Pages (from-to)258-263
Number of pages6
JournalRecent Results in Cancer Research
StatePublished - 1980


Dive into the research topics of 'The rediscovery of DON (6-diazo-5-oxo-L-norleucine).'. Together they form a unique fingerprint.

Cite this